Certara, Inc.

News & Events zu Certara, Inc. (CERT)

$8.350

-0.059 (-0.71%)Zum Schluss

CERT-News

CERT-Events

8/4 08:30

Certara Reaffirms FY26 Revenue View of $367M-$382M

Backs Fy26 revenue view $367M-$382M, consensus $398.63M. The company said, "Certara is reaffirming its revenue growth and updating its adjusted EBITDA margin, adjusted diluted earnings per share, and fully diluted share guidance for the full year 2026, to reflect the divestiture of the Regulatory and Medical Writing business and Continuing Operations reporting."

8/4 08:30

Certara Q2 Revenue $93.3M, Below Expectations

Reports Q2 revenue $93.3M, consensus $98.08M. "This second quarter was about continuing to execute on our commitments. Overall, we are pleased with our ongoing progress transforming Certara into a company we believe can deliver sustainable double-digit growth," said Jon Resnick, Chief Executive Officer. "We completed the divestiture of our Regulatory and Medical Writing business, implemented our two new business units, and taken necessary actions to strengthen our leadership team and our commercial model. Our focus in the second half of the year is customer impact and speed of execution."

7/7 08:30

Certara Partners with Nvidia to Advance AI Platform

Certara (CERT) is partnering with Nvidia (NVDA) to advance Certara's open integrated AI platform. The Nvidia BioNeMo provides access to Nvidia's full life science stack. Within Certara's platform, BioNeMo Agent Toolkit serves as one of several agentic frameworks available to clients, working alongside Certara's biosimulation models, regulatory expertise, and scientific teams to accelerate insight generation.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten